Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310269 · ClinicalTrials.gov registry record
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
A clinical trial, sponsored by Recordati Group.
- Completed
- Registry status
- 152
- Enrollment target
NCT02310269: Completed study, sponsored by Recordati Group.
NCT02310269 is a clinical trial that has completed, run by Recordati Group. The registered enrollment target is 152 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02310269 has completed, sponsored by Recordati Group.
- COMPLETED
- Registry status
- 152 participants
- Enrollment target
Study Summary
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.
Primary Outcome
Number of pasireotide s.c related adverse events and serious adverse events, when administered as monotherapy or in combination with other therapies in patients with Cushing's disease
Interventions
- DRUG Pasireotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2013-03-28 |
| Est. Completion | 2023-07-10 |
What the finished NCT02310269 record still lists
NCT02310269 is an observational study that tracks outcomes without assigning an intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide is the first listed.
NCT02310269 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02310269 about?
NCT02310269 is a clinical study titled "Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease". This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in...
What is the current status of trial NCT02310269?
This trial is currently completed. The enrollment target is 152 participants. The study started on 2013-03-28. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT02310269?
The interventions under investigation include: Pasireotide (DRUG).
Who is sponsoring clinical trial NCT02310269?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI